BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LX1033: Phase II data

Top-line data from the Phase Ib portion of a double-blind, dose-escalation, U.S. Phase I trial in 32 healthy volunteers showed that all 4 doses of LX1033 significantly reduced 5-hydroxyindoleacetic acid (5-HIAA), a biomarker for serotonin production, in blood and...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >